{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:04:00Z","timestamp":1794859440621,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K16095"],"award-info":[{"award-number":["JP20K16095"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K07022"],"award-info":[{"award-number":["JP20K07022"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41429-021-00428-z","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T08:04:17Z","timestamp":1622102657000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics of voriconazole and its alteration by Candida albicans infection in silkworms"],"prefix":"10.1038","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0587-0091","authenticated-orcid":false,"given":"Takeo","family":"Yasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"428_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1\u2013e60.","journal-title":"Clin Infect Dis"},{"key":"428_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/cpt.1012","volume":"104","author":"N Mangal","year":"2018","unstructured":"Mangal N, et al. Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults. Clin Pharm Ther. 2018;104:957\u201365.","journal-title":"Clin Pharm Ther"},{"key":"428_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649\u201363.","journal-title":"Clin Pharmacokinet"},{"key":"428_CR4","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1128\/AAC.01083-10","volume":"55","author":"PF Troke","year":"2011","unstructured":"Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55:4782\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","volume":"18","author":"Y Hamada","year":"2012","unstructured":"Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother. 2012;18:501\u20137.","journal-title":"J Infect Chemother"},{"key":"428_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/cis599","volume":"55","author":"WB Park","year":"2012","unstructured":"Park WB, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080\u20137.","journal-title":"Clin Infect Dis"},{"key":"428_CR7","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","volume":"56","author":"MJ Dolton","year":"2012","unstructured":"Dolton MJ, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56:4793\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR8","doi-asserted-by":"publisher","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","volume":"215","author":"F Stanke-Labesque","year":"2020","unstructured":"Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R, French Society of Pharmacology and Therapeutics. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharm Ther. 2020;215:107627.","journal-title":"Pharm Ther"},{"key":"428_CR9","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1128\/AAC.03820-14","volume":"58","author":"MJP van Wanrooy","year":"2014","unstructured":"van Wanrooy MJP, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58:7098\u2013101.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR10","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1128\/AAC.02830-15","volume":"60","author":"MAE Ventura","year":"2016","unstructured":"Ventura MAE, et al. Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations. Antimicrob Agents Chemother. 2016;60:2727\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR11","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1080\/10428194.2017.1300897","volume":"58","author":"T Yasu","year":"2017","unstructured":"Yasu T, et al. Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Leuk Lymphoma. 2017;58:2731\u201333.","journal-title":"Leuk Lymphoma"},{"key":"428_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1248\/bpb.b19-00834","volume":"43","author":"Y Matsumoto","year":"2020","unstructured":"Matsumoto Y. Facilitating drug discovery in human disease models using insects. Biol Pharm Bull. 2020;43:216\u201320.","journal-title":"Biol Pharm Bull"},{"key":"428_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/1348-0421.12834","volume":"64","author":"C Kaito","year":"2020","unstructured":"Kaito C, Murakami K, Imai L, Furuta K. Animal infection models using non-mammals. Microbiol Immunol. 2020;64:585\u201392.","journal-title":"Microbiol Immunol"},{"key":"428_CR14","doi-asserted-by":"publisher","first-page":"35048","DOI":"10.1007\/s11356-018-3442-8","volume":"25","author":"N Abdelli","year":"2018","unstructured":"Abdelli N, Peng L, Keping C. Silkworm, Bombyx mori, as an alternative model organism in toxicological research. Environ Sci Pollut Res Int. 2018;25:35048\u201354.","journal-title":"Environ Sci Pollut Res Int"},{"key":"428_CR15","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1128\/AAC.48.3.774-779.2004","volume":"48","author":"H Hamamoto","year":"2004","unstructured":"Hamamoto H, et al. Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms. Antimicrob Agents Chemother. 2004;48:774\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ijantimicag.2005.03.008","volume":"26","author":"H Hamamoto","year":"2005","unstructured":"Hamamoto H, et al. Effects of molecular mass and hydrophobicity on transport rates through non-specific pathways of the silkworm larva midgut. Int J Antimicrob Agents. 2005;26:38\u201342.","journal-title":"Int J Antimicrob Agents"},{"key":"428_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2672.2011.05186.x","volume":"112","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto Y, et al. Quantitative evaluation of cryptococcal pathogenesis and antifungal drugs using a silkworm infection model with cryptococcus neoformans. J Appl Microbiol. 2012;112:138\u201346.","journal-title":"J Appl Microbiol"},{"key":"428_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46013-1","volume":"9","author":"H Hamamoto","year":"2019","unstructured":"Hamamoto H, Horie R, Sekimizu K. Pharmacokinetics of anti-infectious reagents in silkworms. Sci Rep. 2019;9:9451.","journal-title":"Sci Rep"},{"key":"428_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/mpat.2002.0494","volume":"32","author":"C Kaito","year":"2002","unstructured":"Kaito C, Akimitsu N, Watanabe H, Sekimizu K. Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Micro Pathog. 2002;32:183\u201390.","journal-title":"Micro Pathog"},{"key":"428_CR20","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1128\/EC.00129-08","volume":"7","author":"N Hanaoka","year":"2008","unstructured":"Hanaoka N, et al. Identification of the putative protein phosphatase gene PTC1 as a virulence-related gene using a silkworm model of Candida albicans infection. Eukaryot Cell. 2008;7:1640\u20138.","journal-title":"Eukaryot Cell"},{"key":"428_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/1348-0421.12668","volume":"63","author":"Y Matsumoto","year":"2019","unstructured":"Matsumoto Y, Sekimizu K. Silkworm as an experimental animal for research on fungal infections. Microbiol Immunol. 2019;63:41\u201350.","journal-title":"Microbiol Immunol"},{"key":"428_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.dci.2018.02.004","volume":"83","author":"G Pan","year":"2018","unstructured":"Pan G, et al. Invertebrate host responses to microsporidia infections. Dev Comp Immunol. 2018;83:104\u201313.","journal-title":"Dev Comp Immunol"},{"key":"428_CR23","doi-asserted-by":"publisher","first-page":"33338","DOI":"10.1074\/jbc.M110.112987","volume":"285","author":"K Ishii","year":"2010","unstructured":"Ishii K, et al. Porphyromonas gingivalis peptidoglycans induce excessive activation of the innate immune system in silkworm larvae. J Biol Chem. 2010;285:33338\u201347.","journal-title":"J Biol Chem"},{"key":"428_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s42003-019-0407-5","volume":"2","author":"Y Matsumoto","year":"2019","unstructured":"Matsumoto Y, Ishii M, Hasegawa S, Sekimizu K. Enterococcus faecalis YM0831 suppresses sucrose-induced hyperglycemia in a silkworm model and in humans. Commun Biol. 2019;2:157.","journal-title":"Commun Biol"},{"key":"428_CR25","first-page":"e01491","volume":"61","author":"SM Rudramurthy","year":"2016","unstructured":"Rudramurthy SM, et al. Pharmacodynamics of voriconazole against wild-type and azole-resistant aspergillus flavus isolates in a nonneutropenic murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 2016;61:e01491\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR26","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1002\/jps.24552","volume":"104","author":"FJ Azeredo","year":"2015","unstructured":"Azeredo FJ, et al. Does the anesthetic urethane influence the pharmacokinetics of antifungal drugs? A population pharmacokinetic investigation in rats. J Pharm Sci. 2015;104:3314\u20138.","journal-title":"J Pharm Sci"},{"key":"428_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cbpc.2008.08.008","volume":"149","author":"H Hamamoto","year":"2009","unstructured":"Hamamoto H, Tonoike A, Narushima K, Horie R, Sekimizu K. Silkworm as a model animal to evaluate drug candidate toxicity and metabolism. Comp Biochem Physiol C Toxicol Pharm. 2009;149:334\u20139.","journal-title":"Comp Biochem Physiol C Toxicol Pharm"},{"key":"428_CR28","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1093\/jac\/dkt229","volume":"68","author":"MJP Geist","year":"2013","unstructured":"Geist MJP, et al. Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother. 2013;68:2592\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"428_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/dmd.31.6.731","volume":"31","author":"SJ Roffey","year":"2003","unstructured":"Roffey SJ, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003;31:731\u201341.","journal-title":"Drug Metab Dispos"},{"key":"428_CR30","doi-asserted-by":"publisher","first-page":"e02586","DOI":"10.1128\/AAC.02586-18","volume":"63","author":"AG Warrilow","year":"2019","unstructured":"Warrilow AG, et al. The evolution of azole resistance in Candida albicans Sterol 14\u03b1-demethylase (CYP51) through incremental amino acid substitutions. Antimicrob Agents Chemother. 2019;63:e02586\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1124\/dmd.108.024240","volume":"37","author":"MR Chaluvadi","year":"2009","unstructured":"Chaluvadi MR, et al. Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium. Drug Metab Dispos. 2009;37:366\u201374.","journal-title":"Drug Metab Dispos"},{"key":"428_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijantimicag.2019.01.006","volume":"53","author":"AG M\u00e4rtson","year":"2019","unstructured":"M\u00e4rtson AG, et al. Posaconazole trough concentrations are not influenced by inflammation: a prospective study. Int J Antimicrob Agents. 2019;53:325\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"428_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cca.2014.12.024","volume":"441","author":"T Naito","year":"2015","unstructured":"Naito T, Yamada T, Mino Y, Kawakami J. Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. Clin Chim Acta. 2015;441:127\u201332.","journal-title":"Clin Chim Acta"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41429-021-00428-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-021-00428-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-021-00428-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:58Z","timestamp":1684618498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-021-00428-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1038\/s41429-021-00428-z","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"6 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}